Details for Patent: 8,536,130

Which drugs does patent 8,536,130 protect, and when does it expire?

Patent 8,536,130 protects NUCYNTA ER and is included in one NDA.

Protection for NUCYNTA ER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 8,536,130

Patent landscape, scope, and claims:

Title:	Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Abstract:	Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Inventor(s):	Christoph; Thomas (Aachen, DE), Friderichs; Elmar (Stolberg, DE), Koegel; Babette-Yvonne (Langerwehe-Hamich, DE), Meen; Murielle (Ayguesvives, FR)
Assignee:	Gruenenthal GmbH (Aachen, DE)
Application Number:	12/850,208
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,536,130
Patent Claim Types: see list of patent claims	Use;

Recent additions to Drugs Protected by US Patent 8,536,130

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE	200533	Aug 25, 2011	RX	Yes						U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

Drugs Protected by US Patent 8,536,130

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 8,536,130

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2007 012 165	Mar 12, 2007

International Family Members for US Patent 8,536,130

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2680771
Cyprus	1115455
Germany	102007012165
Denmark	2117525